Literature DB >> 35065711

Response to Are NKT cells a useful predictor of COVID-19 severity?

Stefanie Kreutmair1, Burkhard Becher2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35065711      PMCID: PMC8783200          DOI: 10.1016/j.immuni.2022.01.012

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


× No keyword cloud information.

Main text

The purpose of our study was to identify immune signatures specific to the immune response against SARS-CoV-2 by subtracting the immune signatures against other pathogens across patients with severe pneumonia. In order to do so, and to specifically interrogate functional features such as cytokine expression and activation/exhaustion states, we generated very broad phenotyping panels that allow the characterization of blood leukocytes. In order to have an unbiased workflow, we did not specifically interrogate certain rare subpopulations of cells such as iNKT cells (defined by CD1d tetramers loaded with α-galactosylceramide; Godfrey et al., 2004). The discovery that the frequency of the FlowSOM-generated CD3+ CD4− CD8− CD56+ T cell cluster has a strong predictive value for patient outcomes in COVID-19 was not anticipated. In our original article, we had used the term “NKT” for T cells that express a natural killer receptor (CD56), and therefore to describe the FlowSOM-generated T cell cluster based on 22 immune cell markers as seen in Kreutmair et al.’s Figure 2B, 7B, S2A, and S2B (Kreutmair et al., 2021). The cluster discriminated from other (both conventional and unconventional) T cells predominantly due to CD56 positivity and CD4 and CD8 negativity, characterizing these cells as CD3+ CD4− CD8− CD56+ next to other markers. As pointed out (Koay et al., 2022’s Figure S1A), gating on CD3+ CD56+ T cells delivers a heterogeneous subset containing TCRγδ T cells, iNKT, cells and MAIT cells. To be more precise and avoid confusion, we corrected the term “NKT” with “CD56+ T cells.” One reason for discrepancies in frequencies and their predictive value for severe COVID-19 in our study compared to the analysis by Koay et al. may be due to the overall approach in how the unconventional T cell subsets were identified. The FlowSOM algorithm, which we used, is designed to work with high-parametric datasets and takes all included markers into account, while Koay et al. defined the populations based on sequential manual gating of 2-dimensional plots. We measured approximately 5% of CD56+ T cells among T cells in healthy controls (Kreutmair et al., 2021’s Figure 5B) compared to approximately 10% detected by Koay et al. (Koay et al., 2022’s Figure S1E), making a direct comparison of the predictive values for severe COVID-19 of the identified subsets difficult. Furthermore, their classification of mild and severe COVID-19 patients (patients admitted to a ward versus an ICU) differed from ours, which was based on World Health Organization (WHO)-based grading of COVID-19 severity. We would like to point out here that the transfer of complex high-parametric algorithm-based population characterizations into daily clinical routines is challenging, where often sequential manual gating using 2-dimensional plots is used to define populations. Therefore, as we had already pointed out in Kreutmair et al., we suggested larger follow-up studies to solidify this measurement as a predictive biomarker for COVID-19 patient outcomes. Koay et al. and others (Zhang et al., 2020) did not find CD56+ T cell frequency to hold predictive value for COVID-19 patient outcomes. However, several reports demonstrated a predictive value for the CD3+ CD56+ T cell subset as well as MAIT cells in COVID-19 (Flament et al., 2021; Li et al., 2020; Notarbartolo et al., 2021; Odak et al., 2020; Parrot et al., 2020; Zingaropoli et al., 2021). This is in line with our data demonstrating reduced frequencies of the CD4− CD8− (Kreutmair et al., 2021’s Figure 2C) and the CD56+ T cell cluster (Kreutmair et al., 2021’s Figure 5B) in severe COVID-19; both clusters include circulating MAIT cells. Taken together, regardless of nomenclature and specific research interests, the unbiased algorithm-based analysis suggested that CD56+ T cells have predictive value for COVID-19 patient outcomes. This cell population appears to include TCRγδ T cells, iNKT cells, and MAIT cells. It would be of interest to have a more fine-grained analysis of these populations and, moreover, to understand their functional significance for disease development.
  10 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.

Authors:  Héloïse Flament; Matthieu Rouland; Lucie Beaudoin; Amine Toubal; Léo Bertrand; Samuel Lebourgeois; Camille Rousseau; Pauline Soulard; Zouriatou Gouda; Lucie Cagninacci; Antoine C Monteiro; Margarita Hurtado-Nedelec; Sandrine Luce; Karine Bailly; Muriel Andrieu; Benjamin Saintpierre; Franck Letourneur; Youenn Jouan; Mustapha Si-Tahar; Thomas Baranek; Christophe Paget; Christian Boitard; Anaïs Vallet-Pichard; Jean-François Gautier; Nadine Ajzenberg; Benjamin Terrier; Frédéric Pène; Jade Ghosn; Xavier Lescure; Yazdan Yazdanpanah; Benoit Visseaux; Diane Descamps; Jean-François Timsit; Renato C Monteiro; Agnès Lehuen
Journal:  Nat Immunol       Date:  2021-02-02       Impact factor: 25.606

3.  Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients.

Authors:  Samuele Notarbartolo; Valeria Ranzani; Alessandra Bandera; Paola Gruarin; Valeria Bevilacqua; Anna Rita Putignano; Andrea Gobbini; Eugenia Galeota; Cristina Manara; Mauro Bombaci; Elisa Pesce; Elena Zagato; Andrea Favalli; Maria Lucia Sarnicola; Serena Curti; Mariacristina Crosti; Martina Martinovic; Tanya Fabbris; Federico Marini; Lorena Donnici; Mariangela Lorenzo; Marilena Mancino; Riccardo Ungaro; Andrea Lombardi; Davide Mangioni; Antonio Muscatello; Stefano Aliberti; Francesco Blasi; Tullia De Feo; Daniele Prati; Lara Manganaro; Francesca Granucci; Antonio Lanzavecchia; Raffaele De Francesco; Andrea Gori; Renata Grifantini; Sergio Abrignani
Journal:  Sci Immunol       Date:  2021-08-10

4.  Single-cell landscape of immunological responses in patients with COVID-19.

Authors:  Ji-Yuan Zhang; Xiang-Ming Wang; Xudong Xing; Zhe Xu; Chao Zhang; Jin-Wen Song; Xing Fan; Peng Xia; Jun-Liang Fu; Si-Yu Wang; Ruo-Nan Xu; Xiao-Peng Dai; Lei Shi; Lei Huang; Tian-Jun Jiang; Ming Shi; Yuxia Zhang; Alimuddin Zumla; Markus Maeurer; Fan Bai; Fu-Sheng Wang
Journal:  Nat Immunol       Date:  2020-08-12       Impact factor: 25.606

5.  Major reduction of NKT cells in patients with severe COVID-19 pneumonia.

Authors:  Maria Antonella Zingaropoli; Valentina Perri; Patrizia Pasculli; Francesco Cogliati Dezza; Parni Nijhawan; Giulia Savelloni; Giuseppe La Torre; Claudia D'Agostino; Fabio Mengoni; Miriam Lichtner; Maria Rosa Ciardi; Claudio Maria Mastroianni
Journal:  Clin Immunol       Date:  2020-11-13       Impact factor: 3.969

6.  Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.

Authors:  Stefanie Kreutmair; Susanne Unger; Nicolás Gonzalo Núñez; Florian Ingelfinger; Chiara Alberti; Donatella De Feo; Sinduya Krishnarajah; Manuel Kauffmann; Ekaterina Friebel; Sepideh Babaei; Benjamin Gaborit; Mirjam Lutz; Nicole Puertas Jurado; Nisar P Malek; Siri Goepel; Peter Rosenberger; Helene A Häberle; Ikram Ayoub; Sally Al-Hajj; Jakob Nilsson; Manfred Claassen; Roland Liblau; Guillaume Martin-Blondel; Michael Bitzer; Antoine Roquilly; Burkhard Becher
Journal:  Immunity       Date:  2021-05-09       Impact factor: 31.745

7.  Reappearance of effector T cells is associated with recovery from COVID-19.

Authors:  Ivan Odak; Joana Barros-Martins; Berislav Bošnjak; Klaus Stahl; Sascha David; Olaf Wiesner; Markus Busch; Marius M Hoeper; Isabell Pink; Tobias Welte; Markus Cornberg; Matthias Stoll; Lilia Goudeva; Rainer Blasczyk; Arnold Ganser; Immo Prinz; Reinhold Förster; Christian Koenecke; Christian R Schultze-Florey
Journal:  EBioMedicine       Date:  2020-07-07       Impact factor: 8.143

8.  Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.

Authors:  Mingyue Li; Weina Guo; Yalan Dong; Xiaobei Wang; Die Dai; Xingxing Liu; Yiquan Wu; Mengmeng Li; Wenjing Zhang; Haifeng Zhou; Zili Zhang; Lan Lin; Zhenyu Kang; Ting Yu; Chunxia Tian; Renjie Qin; Yang Gui; Feng Jiang; Heng Fan; Vigo Heissmeyer; Alexey Sarapultsev; Lin Wang; Shanshan Luo; Desheng Hu
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

9.  MAIT cell activation and dynamics associated with COVID-19 disease severity.

Authors:  Tiphaine Parrot; Jean-Baptiste Gorin; Andrea Ponzetta; Kimia T Maleki; Tobias Kammann; Johanna Emgård; André Perez-Potti; Takuya Sekine; Olga Rivera-Ballesteros; Sara Gredmark-Russ; Olav Rooyackers; Elin Folkesson; Lars I Eriksson; Anna Norrby-Teglund; Hans-Gustaf Ljunggren; Niklas K Björkström; Soo Aleman; Marcus Buggert; Jonas Klingström; Kristoffer Strålin; Johan K Sandberg
Journal:  Sci Immunol       Date:  2020-09-28

10.  Are NKT cells a useful predictor of COVID-19 severity?

Authors:  Hui-Fern Koay; Nicholas A Gherardin; Thi H O Nguyen; Wuji Zhang; Jennifer R Habel; Rebecca Seneviratna; Fiona James; Natasha E Holmes; Olivia C Smibert; Claire L Gordon; Jason A Trubiano; Katherine Kedzierska; Dale I Godfrey
Journal:  Immunity       Date:  2022-01-19       Impact factor: 31.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.